Comments on:

Generic competition, charges cut Merck Q4 profit

Back to the article » |
Merck & Co.'s fourth-quarter profit fell 7 percent because of hits from generic competition and one-time charges, and the company pushed back plans for seeking approval of a key experimental osteoporosis drug. The quarterly results beat Wall Street expectations, but Merck shares fell Friday as investors learned the company is reviewing safety and efficacy data from a crucial late-stage patient...

To learn more about commenting on WashingtonExaminer.com and our community guidelines, please see our comments FAQ.